MannKind Corp (MNKD)

• Market cap: $1.89B
• 1 day: 8.73%
• 5 days: 4.10%
• 1 month: -0.44%
• 3 months: 3.79%
• 6 months: 40.95%
• Year to date: 74.74%
• 1 year: 105.09%
• 5 years: 396.38%
• 10 years: -74.54%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Employees: 414

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

111% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 19

60% more call options, than puts

Call options by funds: $17M | Put options by funds: $10.6M

52% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 52

33% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 4 (+1) [Q3]

33% more capital invested

Capital invested by funds: $730M [Q2] → $970M (+$240M) [Q3]

10% more funds holding

Funds holding: 208 [Q2] → 229 (+21) [Q3]

4.8% more ownership

Funds ownership: 51.33% [Q2] → 56.13% (+4.8%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 31% upside
• Avg. target: $9.50 39% upside
• High target: $10 46% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Tiago Fauth 72% 1-year accuracy 13 / 18 met price target	31% upside $9	Overweight Initiated	20 Dec 2024
RBC Capital Gregory Renza 40% 1-year accuracy 32 / 81 met price target	46% upside $10	Outperform Upgraded	19 Dec 2024